Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

@inproceedings{Scatena2009VoreloxinAF,
  title={Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo},
  author={Caroline D. Scatena and Jeffrey L. Kumer and Jennifer P. Arbitrario and Anthony R. Howlett and Rachael Elizabeth Hawtin and Judith Ann Fox and Jeffrey A. Silverman},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2009}
}

• Caroline D. Scatena, Jeffrey L. Kumer, +4 authors Jeffrey A. Silverman
• Published 2009 in Cancer Chemotherapy and Pharmacology
• DOI:10.1007/s00280-009-1234-z

Voreloxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, inducing site-selective DNA damage. Voreloxin is in clinical studies, as a single agent and in combination with cytarabine, for the treatment of acute myeloid leukemia (AML). The preclinical studies reported here were performed to investigate the activity of voreloxin alone and in combination with cytarabine, in support of the clinical program. Is single agent voreloxin active in… CONTINUE READING

Save to Library

Create Alert

Cite

View on Springer